Literature DB >> 21089745

Respiratory distress in newborn: evaluation of chest X-rays.

M Roggini1, D Pepino, M D'Avanzo, G M Andreoli, S Ceccanti, P Capocaccia.   

Abstract

We discuss the anatomic and pathophysiological patterns of preterm and term newborn. Particular attention is directed to technical artefacts relating to the interpretation of chest radiography. We analyze the reading of chest X-Ray of preterm with low birth weight and poor lung maturation. Are also taken into account X-Ray features relating to alveolar "recruitment" and radiographic changes after surfactant's administration. We highlight the most important paintings of bruncopulmonary dysplasia and its evolution. The most frequent neonatal pulmonary inflammation and thoraco-pulmonary malformation, that may affect more the neonatologist, are mentioned. We discuss the new diagnostic approach with non invasive techniques (ultrasound) in the neonatal distress. Some easily recognizable congenital heart disease are finally describes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21089745

Source DB:  PubMed          Journal:  Minerva Pediatr        ISSN: 0026-4946            Impact factor:   1.312


  3 in total

1.  New surfactant with SP-B and C analogs gives survival benefit after inactivation in preterm lambs.

Authors:  Matthias Seehase; Jennifer J P Collins; Elke Kuypers; Reint K Jellema; Daan R M G Ophelders; Olga L Ospina; J Perez-Gil; Federico Bianco; Raffaella Garzia; Roberta Razzetti; Boris W Kramer
Journal:  PLoS One       Date:  2012-10-16       Impact factor: 3.240

2.  Assessment of chest X-ray images in newborns with respiratory disorders.

Authors:  Łukasz Maciej Czarnecki
Journal:  Kardiochir Torakochirurgia Pol       Date:  2015-03-31

3.  Early surfactant replacement guided by lung ultrasound in preterm newborns with RDS: the ULTRASURF randomised controlled trial.

Authors:  Javier Rodriguez-Fanjul; I Jordan; M Balaguer; A Batista-Muñoz; M Ramon; S Bobillo-Perez
Journal:  Eur J Pediatr       Date:  2020-07-24       Impact factor: 3.183

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.